Table I.
Clinical and demographic characteristics of the renal transplant recipients on tacrolimus-based immunosuppression in the different periods after transplantation.
| Period after transplantation | |||
|---|---|---|---|
| Parameters | 6 months | 12 months | 24 months |
| Gender (male/female) | 35/18 | 35/18 | 35/18 |
| Age (years) | 39 (33–48) | 40 (34–49) | 39 (35–50) |
| Donor type (living/deceased) | 41/12 | 41/12 | 41/12 |
| Body weight (kg) | 72 (65.5–77.5) | 73 (66–80) | 73.5 (66.3–84) |
| Cre (µmol/l) | 136 (115–164) | 122 (108–154) | 141 (114–157) |
| eGFR (ml/min/1.73 m2) | 49.36 (40.54–58.42) | 51.69 (44.46–59.02) | 48.48 (41.70–56.65) |
| Ure (mmol/l) | 8.20 (6.70–9.70) | 7.70 (6.48–10.13) | 8.00 (5.90–11.00) |
| Dose of Tac (mg/kg/day) | 0.06 (0.05–0.09) | 0.05 (0.04–0.07) | 0.04 (0.03–0.07) |
| C0 of Tac (ng/ml) | 7.40 (6.20–8.90) | 7.25 (5.68–8.45) | 6.45 (5.50–7.75) |
| C0/D of Tac [(ng/ml)/(mg/kg/day)] | 110.92 (82.69–164.81) | 129.10 (85.72–207.91) | 146.43 (114.31–204.43) |
| Dose of Pre (mg/kg/day) | 0.15 (0.14–0.17) | 0.14 (0.13–0.16) | 0.14 (0.12–0.15) |
| Dose of MPA (mg/day)a | 1080 (720–1440) | 1080 (720–1440) | 1080 (720–1080) |
| CYP 3A5 genotype (*1*3/*3*3) | 11/42 | 11/42 | 11/42 |
| ABCB1 genotype (CC/CT/TT) | 11/32/10 | 11/32/10 | 11/32/10 |
Data are expressed as median (interquatile range) or number; eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.
a
MMF dose was calculated on the basis of the MPA dose. Cre, serum creatinine level; eGFR, estimated glomerular filtration rate; Ure, serum urea level; Tac, tacrolimus; Pre, prednisone; MMF, mycophenolate mofetil; MPA, mycophenolic acid; C0, tacrolimus trough concentration; C0/D, dose-adjusted trough concentration of tacrolimus; CYP 3A5, cytochrome P450 3A5; ABCB1, ATP-binding cassette transporter B1.